Literature DB >> 28379898

Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer.

Bhumika Wadhwa1, Ubaid Makhdoomi, Ram Vishwakarma, Fayaz Malik.   

Abstract

The serine/threonine protein kinase B (PKB), also known as Akt, is one of the multifaceted kinases in the human kinome, existing in three isoforms. PKB plays a vital role in phosphoinositide 3-kinase (PI3K)-mediated oncogenesis in various malignancies and is one of the attractive targets for cancer drug discovery. Recent studies have shown that the functional significance of an individual isoform of PKB is not redundant in cancer. It has been found that PKB isoforms play distinct roles in the regulation of cellular invasion and migration during tumorigenesis. PKB activation plays a central role during epithelial-mesenchymal transition, a cellular program required for the cancer cell invasion and migration. However, the differential behavior of each PKB isoform has been shown in the regulation of epithelial-mesenchymal transition. Recent studies have suggested that PKBα (Akt1) plays a conflicting role in tumorigenesis by acting either as a pro-oncogenic factor by suppressing the apoptotic machinery or by restricting tumor invasion. PKBβ (Akt2) promotes cell migration and invasion and similarly PKBγ (Akt3) has been reported to promote tumor migration. As PKB is known for its pro-oncogenic properties, it needs to be unraveled how three isoforms of PKB compensate during tumor progression. In this review, we attempted to sum up how different isoforms of PKB play a role in cancer progression, metastasis, and drug resistance.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28379898     DOI: 10.1097/CAD.0000000000000496

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  10 in total

Review 1.  RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

2.  The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131.

Authors:  Jordi Vilardell; Cristina Girardi; Oriano Marin; Giorgio Cozza; Lorenzo A Pinna; Maria Ruzzene
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

3.  Synthesis and PI 3-Kinase Inhibition Activity of Some Novel 2,4,6-Trisubstituted 1,3,5-Triazines.

Authors:  Ronald A Nelson; Taylor Schronce; Yue Huang; Alanoud Albugami; George Kulik; Mark E Welker
Journal:  Molecules       Date:  2018-07-04       Impact factor: 4.411

Review 4.  Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.

Authors:  Choudhary Harsha; Kishore Banik; Hui Li Ang; Sosmitha Girisa; Rajesh Vikkurthi; Dey Parama; Varsha Rana; Bano Shabnam; Elina Khatoon; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

5.  Akt1 regulates pulmonary fibrosis via modulating IL-13 expression in macrophages.

Authors:  Yunjuan Nie; Yudong Hu; Kaikai Yu; Dan Zhang; Yinze Shi; Yaolin Li; Lei Sun; Feng Qian
Journal:  Innate Immun       Date:  2019-07-12       Impact factor: 2.680

Review 6.  Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects.

Authors:  Silviu Stanciu; Florentina Ionita-Radu; Constantin Stefani; Daniela Miricescu; Iulia-Ioana Stanescu-Spinu; Maria Greabu; Alexandra Ripszky Totan; Mariana Jinga
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

7.  Synthesis and PI3 Kinase Inhibition Activity of Some Novel Trisubstituted Morpholinopyrimidines.

Authors:  Emily W Wright; Ronald A Nelson; Yelena Karpova; George Kulik; Mark E Welker
Journal:  Molecules       Date:  2018-07-10       Impact factor: 4.411

Review 8.  Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

9.  T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma.

Authors:  Sheng Zhong; Bo Wu; Jiahui Li; Xinhui Wang; Shanshan Jiang; Fangfei Hu; Gaojing Dou; Yuan Zhang; Chunjia Sheng; Gang Zhao; Yunqian Li; Yong Chen
Journal:  Aging (Albany NY)       Date:  2019-10-26       Impact factor: 5.682

10.  Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model.

Authors:  Motoyasu Saji; Caroline S Kim; Chaojie Wang; Xiaoli Zhang; Tilak Khanal; Kevin Coombes; Krista La Perle; Sheue-Yann Cheng; Philip N Tsichlis; Matthew D Ringel
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.